02-12181. Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Assay for the Proteolytic Activity of Serotype A Neurotoxin From Clostridium Botulinum  

  • Start Preamble

    AGENCY:

    Department of the Army, DOD.

    ACTION:

    Notice.

    SUMMARY:

    In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 5,965,699 entitled “Assay for the Proteolytic Activity of Serotype A Neurotoxin from Clostridium Botulinum” issued October 12, 1999. The United States Government, as represented by the Secretary of the Army has rights in this invention.

    ADDRESSES:

    Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    A label-based assay is described , through modifications of substrate structure and derivatization of serum albumin, which can be used to determine type A proteolytic activity without separation of products.

    Start Signature

    Luz D. Ortiz,

    Army Federal Register Liaison Officer.

    End Signature End Supplemental Information

    [FR Doc. 02-12181 Filed 5-15-02; 8:45 am]

    BILLING CODE 3710-08-M

Document Information

Published:
05/16/2002
Department:
Army Department
Entry Type:
Notice
Action:
Notice.
Document Number:
02-12181
Pages:
34913-34913 (1 pages)
PDF File:
02-12181.pdf